Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

    Current refinement(s):

    Records 1 - 3 / 3

    • help
    • print

      Print search results

    • export

      Export search results

    Check title to add to marked list
    One health approach to Rift Valley fever vaccine development
    Kortekaas, J.A. - \ 2014
    Antiviral Research 106 (2014)24. - ISSN 0166-3542 - p. 24 - 32.
    lethal virus challenge - saudi-arabia - immune-responses - rhesus macaques - mp-12 vaccine - south-africa - enzootic hepatitis - northeastern kenya - ifnar(-/-) mice - rvfv infection
    Since its discovery in the 1930s, Rift Valley fever virus (RVFV) spread across the African continent and invaded the Arabian Peninsula and several islands off the coast of Southeast Africa. The virus causes recurrent outbreaks in these regions, and its continued spread is of global concern. Next-generation veterinary vaccines of improved efficacy and safety are being developed that can soon be used for the widespread vaccination of livestock. However, due to regulatory and economic challenges, vaccine manufacturers have been reluctant to develop a human vaccine. Recent innovations in veterinary vaccinology, animal models and licensing strategies can now be used to overcome these hurdles. This paper reviews the historical impact of RVFV on human health and proposes strategies to develop and license a next-generation vaccine for both animals and humans
    Vertical transmission of Rift Valley Fever Virus without detectable maternal viremia
    Antonis, A.F.G. ; Kortekaas, J.A. ; Kant-Eenbergen, H.C.M. ; Vloet, R.P.M. ; Vogel-Brink, A. ; Stockhofe, N. ; Moormann, R.J.M. - \ 2013
    Vector-Borne and Zoonotic Diseases 13 (2013)8. - ISSN 1530-3667 - p. 601 - 606.
    enzootic hepatitis - sheep - cattle - lambs - pathogenesis - pathology - vaccines - vectors - illness
    Rift Valley fever virus (RVFV) is a zoonotic bunyavirus that causes abortions in domesticated ruminants. Sheep breeds exotic to endemic areas are reportedly the most susceptible to RVFV infection. Within the scope of a risk assessment program of The Netherlands, we investigated the susceptibility of a native breed of gestating sheep to RVFV infection. Ewes were infected experimentally during the first, second, or third trimester of gestation. Mortality was high among ewes that developed viremia. Four of 11 inoculated ewes, however, did not develop detectable viremia nor clinical signs and did not seroconvert for immunoglobulin G (IgG) or IgM antibodies. Surprisingly, these ewes were found to contain viral RNA in maternal and fetal organs, and the presence of live virus in fetal organs was demonstrated by virus
    Efficacy of three candidate Rift Valley fever vaccines in sheep
    Kortekaas, J.A. ; Antonis, A.F.G. ; Kant-Eenbergen, H.C.M. ; Vloet, R.P.M. ; Vogel-Brink, A. ; Oreshkova, N.D. ; Boer, S.M. de; Bosch, B.J. ; Moormann, R.J.M. - \ 2012
    Vaccine 30 (2012)23. - ISSN 0264-410X - p. 3423 - 3429.
    north-american mosquitos - enzootic hepatitis - rhesus macaques - virus - disease - protein - transcription - protection - challenge - africa
    Rift Valley fever virus (RVFV) is a mosquito-transmitted Bunyavirus that causes high morbidity and mortality among ruminants and humans. The virus is endemic to the African continent and the Arabian Peninsula and continues to spread into new areas. The explosive nature of RVF outbreaks requires that vaccines provide swift protection after a single vaccination. We recently developed several candidate vaccines and here report their efficacy in lambs within three weeks after a single vaccination. The first vaccine comprises the purified ectodomain of the Gn structural glycoprotein formulated in a water-in-oil adjuvant. The second vaccine is based on a Newcastle disease virus-based vector that produces both RVFV structural glycoproteins Gn and Gc. The third vaccine comprises a recently developed nonspreading RVFV. The latter two vaccines were administered without adjuvant. The inactivated whole virus-based vaccine produced by Onderstepoort Biological Products was used as a positive control. Five out of six mock-vaccinated lambs developed high viremia and fever and one lamb succumbed to the challenge infection. A single vaccination with each vaccine resulted in a neutralizing antibody response within three weeks after vaccination and protected lambs from viremia, pyrexia and mortality.
    Check title to add to marked list

    Show 20 50 100 records per page

     
    Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.